MXCT
Maxcyte, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Maxcyte, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: Iqvia Holdings Inc., Incyte Corp, Charles River Laboratories International, Inc. and 3 more; of Maxcyte, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Iqvia Holdings Inc., Incyte Corp, Charles River Laboratories International, Inc. and 3 more; of Maxcyte, Inc.'s 6 closest co-movers, none share that code.
+9.45%
vs ±81.8% implied · ×0.12
shaded = implied · ▲▼ = realized
Maxcyte, Inc.
1.44
Tall tick = annual report · Source: EDGAR
Linked news
News| Manager | Value | % base | |
|---|---|---|---|
| Capricorn Fund Managers | $10.1M | 12.90% | 0.00% |
| Vitruvian Partners | $6.2M | 7.94% | 0.00% |
| Vanguardindex-like | $5.0M | 6.34% | +1.24% |
| Morgan Stanley | $4.5M | 5.81% | +0.16% |
| Mudita | $4.1M | 5.30% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Capricorn Fund Managers | $10.1M | 12.90% | 0.00% |
| Vitruvian Partners | $6.2M | 7.94% | 0.00% |
| Vanguardindex-like | $5.0M | 6.34% | +1.24% |
| Morgan Stanley | $4.5M | 5.81% | +0.16% |
| Mudita | $4.1M | 5.30% | 0.00% |
Bull2
Bear1
Expected move
No implied move.